Thyas has raised JPY 300 million in Series A3 financing with participation from Kyoto University Innovation Capital Co., Ltd., and D3 LLC.

The funds will be used for accelerating the research and development including preclinical studies of iPS cell-derived immune cell therapy and discovery research of new pipelines for the treatment of solid cancers and infectious diseases.  In addition to R&D, Thyas further strives for business development and aims to deliver the early clinical applications to patients as soon as possible.